Company Filing History:
1 out of 295 
2 out of 832,812 Years Active: 2017-2018
Title: Matthew Feldhammer: Innovator in Immunotherapy
Introduction
Matthew Feldhammer is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of immunotherapy, particularly through his innovative work on TC-PTP inhibitors. With a total of 3 patents to his name, Feldhammer is recognized for his dedication to advancing medical science.
Latest Patents
Feldhammer's latest patents focus on TC-PTP inhibitors as antigen-presenting cell (APC) activators for immunotherapy. The invention encompasses a novel class of compounds that inhibit the TC-PTP enzyme. These compounds are designed to be included in pharmaceutical compositions aimed at treating or preventing TC-PTP mediated diseases, including cancer. The methods developed utilize these inhibitors to activate antigen-presenting cells, such as dendritic cells, for applications in immunotherapeutic treatments.
Career Highlights
Throughout his career, Feldhammer has worked with esteemed institutions, including the Royal Institution for the Advancement of Learning/McGill University. His work has been pivotal in the development of new therapeutic strategies that leverage the immune system to combat diseases.
Collaborations
Feldhammer has collaborated with notable colleagues, including Michel L Tremblay and Claudia Penafuerte. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Matthew Feldhammer stands out as an innovative inventor in the field of immunotherapy. His work on TC-PTP inhibitors has the potential to significantly impact the treatment of cancer and other diseases. His contributions reflect a commitment to improving healthcare through scientific innovation.